Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa

被引:19
|
作者
Jassat, Waasila [1 ,2 ]
Karim, Salim S. Abdool [3 ,4 ]
Ozougwu, Lovelyn [1 ,2 ]
Welch, Richard [1 ,2 ]
Mudara, Caroline [1 ]
Masha, Maureen [1 ,2 ]
Rousseau, Petro [5 ]
Wolmarans, Milani [5 ]
Selikow, Anthony [6 ]
Govender, Nevashan [1 ]
Walaza, Sibongile [1 ,7 ]
von Gottberg, Anne [1 ,8 ]
Wolter, Nicole [1 ,8 ]
Pisa, Pedro Terrence [2 ,9 ]
Sanne, Ian [2 ,10 ]
Govender, Sharlene [2 ]
Blumberg, Lucille [1 ,2 ]
Cohen, Cheryl [1 ]
Groome, Michelle J. [1 ,8 ]
机构
[1] Natl Inst Communicable Dis, Div Natl Hlth Lab Serv, 1 Modderfontein Rd, ZA-2192 Johannesburg, South Africa
[2] Right Care, Pretoria, South Africa
[3] Ctr AIDS Programme Res South Afr, Durban, South Africa
[4] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA
[5] Natl Dept Hlth, Pretoria, South Africa
[6] CSIR, Pretoria, South Africa
[7] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa
[8] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa
[9] Univ Pretoria, Fac Hlth Sci, Dept Human Nutr & Dietet, Pretoria, South Africa
[10] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Clin HIV Res Unit, Johannesburg, South Africa
关键词
COVID-19; hospital admissions; mortality; Omicron BA; 4; 5;
D O I
10.1093/cid/ciac921
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Admission incidence risk and in-hospital mortality decreased in the Omicron BA.1/BA.2 wave, reducing even further in the Omicron BA.4/BA.5 wave. Mortality risk was lower in those with natural infection and vaccination, declining further as the number of vaccine doses increased. Background In this study, we compared admission incidence risk and the risk of mortality in the Omicron BA.4/BA.5 wave to previous waves. Methods Data from South Africa's SARS-CoV-2 case linelist, national COVID-19 hospital surveillance system, and Electronic Vaccine Data System were linked and analyzed. Wave periods were defined when the country passed a weekly incidence of 30 cases/100 000 population. In-hospital case fatality ratios (CFRs) during the Delta, Omicron BA.1/BA.2, and Omicron BA.4/BA.5 waves were compared using post-imputation random effect multivariable logistic regression models. Results The CFR was 25.9% (N = 37 538 of 144 778), 10.9% (N = 6123 of 56 384), and 8.2% (N = 1212 of 14 879) in the Delta, Omicron BA.1/BA.2, and Omicron BA.4/BA.5 waves, respectively. After adjusting for age, sex, race, comorbidities, health sector, and province, compared with the Omicron BA.4/BA.5 wave, patients had higher risk of mortality in the Omicron BA.1/BA.2 wave (adjusted odds ratio [aOR], 1.3; 95% confidence interval [CI]: 1.2-1.4) and Delta wave (aOR, 3.0; 95% CI: 2.8-3.2). Being partially vaccinated (aOR, 0.9; 95% CI: .9-.9), fully vaccinated (aOR, 0.6; 95% CI: .6-.7), and boosted (aOR, 0.4; 95% CI: .4-.5) and having prior laboratory-confirmed infection (aOR, 0.4; 95% CI: .3-.4) were associated with reduced risks of mortality. Conclusions Overall, admission incidence risk and in-hospital mortality, which had increased progressively in South Africa's first 3 waves, decreased in the fourth Omicron BA.1/BA.2 wave and declined even further in the fifth Omicron BA.4/BA.5 wave. Mortality risk was lower in those with natural infection and vaccination, declining further as the number of vaccine doses increased.
引用
收藏
页码:1468 / 1475
页数:8
相关论文
共 50 条
  • [31] Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States
    Di Fusco, Manuela
    Marczell, Kinga
    Thoburn, Elizabeth
    Wiemken, Timothy. L. L.
    Yang, Jingyan
    Yarnoff, Benjamin
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 509 - 524
  • [32] Molecular dynamic and docking study of chemical structure of new corona viruses lineages of Omicron BA.n sub-variants (n=1-5); BA.4 or BA.5 strains exhibit the most concern
    Monajjemi, Majid
    Shahriari, Sara
    Mollaamin, Fatemeh
    Najaflou, Narges
    JOURNAL OF THE CHILEAN CHEMICAL SOCIETY, 2023, 68 (03): : 5924 - 5933
  • [33] Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022-2023 Winter Season
    Moss, Stephen
    Jurkowicz, Menucha
    Nemet, Ital
    Atari, Nofar
    Kliker, Limor
    Abd-Elkader, Bayan
    Gonen, Tal
    Martin, Emily Toth
    Lustig, Yaniv
    Regev-Yochay, Gili
    Mandelboim, Michal
    VACCINES, 2023, 11 (10)
  • [34] Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection
    Cheng, Samuel S. M.
    Mok, Chris K. P.
    Li, John K. C.
    Ng, Susanna S.
    Lam, Bosco H. S.
    Jeevan, Trushar
    Kandeil, Ahmed
    Pekosz, Andrew
    Chan, Karl C. K.
    Tsang, Leo C. H.
    Ko, Fanny W.
    Chen, Chunke
    Yiu, Karen
    Luk, Leo L. H.
    Chan, Ken K. P.
    Webby, Richard J.
    Poon, Leo L. M.
    Hui, David S. C.
    Peiris, Malik
    JOURNAL OF CLINICAL VIROLOGY, 2022, 156
  • [35] In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT-qPCR assays for SARS-CoV-2 detection using whole genome sequencing
    Sharma, Divya
    Notarte, Kin, I
    Fernandez, Rey A.
    Lippi, Giuseppe
    Gromiha, Michael M.
    Henry, Brandon M.
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [36] Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era
    Sridhara, Srilekha
    Gungor, Ahmet B.
    Erol, Halil K.
    Al-Obaidi, Mohanad
    Zangeneh, Tirdad T.
    Bedrick, Edward J.
    Ariyamuthu, Venkatesh K.
    Shetty, Aneesha
    Qannus, Abd A.
    Mendoza, Katherine
    Murugapandian, Sangeetha
    Gupta, Gaurav
    Tanriover, Bekir
    PLOS ONE, 2023, 18 (04):
  • [37] Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case-Control Study Based on the French National Health Data System
    Semenzato, Laura
    Botton, Jeremie
    Le Vu, Stephane
    Jabagi, Marie-Joelle
    Cuenot, Francois
    Drouin, Jerome
    Dray-Spira, Rosemary
    Weill, Alain
    Zureik, Mahmoud
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (10):
  • [38] Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and BA.2 subvariants
    Maltezou, Helena C.
    Gamaletsou, Maria N.
    Giannouchos, Theodoros, V
    Koukou, Dimitra-Maria
    Sourri, Flora
    Karapanou, Amalia
    Lemonakis, Nikolaos
    Souliotis, Kyriakos
    Lourida, Athanasia
    Panagopoulos, Periklis
    Hatzigeorgiou, Dimitrios
    Sipsas, Nikolaos, V
    VACCINE, 2024, 42 (17) : 3693 - 3698
  • [39] Ten rapid antigen tests for SARS-CoV-2 widely differ in their ability to detect Omicron-BA.4 and -BA.5
    Krenn, Franziska
    Daechert, Christopher
    Badell, Irina
    Lupoli, Gaia
    Oeztan, Gamze Naz
    Feng, Tianle
    Schneider, Nikolas
    Huber, Melanie
    Both, Hanna
    Spaeth, Patricia M. M.
    Muenchhoff, Maximilian
    Graf, Alexander
    Krebs, Stefan
    Blum, Helmut
    Durner, Jurgen
    Czibere, Ludwig
    Kaderali, Lars
    Keppler, Oliver T. T.
    Baldauf, Hanna-Mari
    Osterman, Andreas
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2023, 212 (05) : 323 - 337
  • [40] Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination
    Astakhova, Ekaterina A.
    Morozov, Alexey A.
    Byazrova, Maria G.
    Sukhova, Maria M.
    Mikhailov, Artem A.
    Minnegalieva, Aygul R.
    Gorchakov, Andrey A.
    Filatov, Alexander V.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)